Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28111767 | 0.97 | CA2 (0.41) | CA2TSHRTDP1CA5ACA5B | |
| SCHEMBL9192869 | 0.97 | CA2 (0.41) | CA2TSHRTDP1CA5ACA5B | |
| SCHEMBL27569711 | 0.97 | CA2 (0.41) | CA2TSHRTDP1CA5ACA5B | |
| SCHEMBL28004753 | 0.93 | CA2 (0.39) | CA2TSHRTDP1CA5ACA5B | |
| Ammonia Solution, Strong SCHEMBL29229399 | 0.93 | CA2 (0.39) | CA2TSHRTDP1CA5ACA5B | |
| SCHEMBL28265378 | 0.93 | CA2 (0.39) | CA2TSHRTDP1CA5ACA5B | |
| SCHEMBL28087456 | 0.93 | CA2 (0.39) | CA2TSHRTDP1CA5ACA5B | |
| SCHEMBL3067997 | 0.93 | CA2 (0.44) | CA2TSHRTDP1CA5ACA5B | |
| Water SCHEMBL10356243 | 0.90 | CA2 (0.37) | CA2TSHRTDP1 | |
| SCHEMBL23880589 | 0.90 | CA2 (0.41) | CA2TSHRTDP1CA5ACA5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262172-B2 | Macrolides | GLAXO GROUP LIMITED (GB) | 2007-08-28 | — | — | US | disclosed |
| EP-1328535-B1 | MACROLIDES | GLAXO GROUP LTD (GB) | 2007-08-15 | — | — | EP | disclosed |
| US-20040254124-A1 | Macrolides | PLIVA D.D. (HR) | 2004-12-16 | — | — | US | disclosed |
| EP-1328535-A1 | MACROLIDES | GLAXO GROUP LIMITED (GB) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002032917-A1 | MACROLIDES | GLAXO GROUP LIMITED (GB) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254124-A1 | Macrolides | OGFOD1, TLR7, MALT1 | CA2 1031/4885TSHR 687/4885TDP1 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.